SkinBioTherapeutics plc (LSE:SBTX) said trading has started well in the current financial year, prompting the company to reaffirm its full-year expectations for 2026. Management confirmed that revenue remains forecast at £6.2 million, with adjusted EBITDA projected at £0.7 million, in line with previous guidance.
The outlook reflects continued progress in strengthening the company’s position within the skincare and gut–skin health markets. Growth is being supported by an expanding product portfolio, commercial partnerships, and strategic initiatives aimed at widening distribution and enhancing brand visibility across key channels.
Despite the positive operational update, SkinBioTherapeutics continues to face financial pressures, including ongoing losses and cash outflows. Market indicators remain cautious, with technical trends signalling weakness. While recent corporate actions and strategic developments could provide longer-term benefits, improved financial performance will be required before sentiment meaningfully shifts.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life sciences company specialising in skin health technologies. The business is built around its proprietary SkinBiotix® platform, developed at the University of Manchester, and operates across cosmetic skincare and food supplements targeting the gut–skin axis. Its AxisBiotix™ products are distributed through partnerships, retail outlets such as Superdrug, and online platforms including Amazon, alongside a strategy of selective acquisitions to expand reach and capabilities.
Leave a Reply